Scientists from the University of South Florida (USF) are exploring the therapeutic potential of bacterial toxins derived from microscopic marine creatures found in Antarctic waters. These organisms, known as ascidians or sea squirts, produce toxins as a natural defence mechanism. Early research suggests these compounds could be repurposed to combat melanoma, the most aggressive form of skin cancer.
A team from USF recently concluded a six-week research expedition to Antarctica, where they collected samples of these invertebrates. Professor Brian Baker, a chemistry expert at USF, explained that preliminary studies have demonstrated the toxins' ability to eliminate melanoma cells in mice. Crucially, these tests indicated that the toxins targeted cancer cells without causing harm to the animals, suggesting a promising physiological profile for drug development.
The journey from initial discovery to an approved human medication is extensive and subject to stringent regulatory processes. Professor Baker noted that while the current findings are encouraging, significant further research is required. This includes conducting larger studies in mice, potentially expanding to other animal models, and rigorously proving safety before any human trials can commence. The knowledge gained from the recent expedition, which involved divers descending to depths of up to 130 feet in challenging conditions, is expected to accelerate this lengthy process.
A major hurdle lies in the scalability of toxin production. The researchers found that a substantial collection of sea squirts yielded only a minute quantity of the active metabolite. Collecting the necessary hundreds of milligrams to grams of material directly from the Antarctic environment is ecologically unsustainable. Therefore, a critical next step for the team, which includes partnerships with the Desert Research Institute and the Scripps Institution of Oceanography, will be to develop methods for synthetically reproducing the toxin in a laboratory setting.
Melanoma is a serious health concern in the UK. According to Cancer Research UK, there are approximately 16,700 new cases of melanoma skin cancer diagnosed each year in the UK, with around 2,300 deaths annually. While current treatments include surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy, the search for novel, more effective options continues. Discoveries from natural sources have historically been a significant contributor to drug development, with over half of all FDA-approved drugs originating from nature. This research aligns with a long-standing tradition of exploring marine biology for potential medical breakthroughs.